Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 19 2021

Full Issue

Perspectives: Exposing The Secrets Of The Pharmaceutical Industry

Read recent commentaries about drug-cost issues.

The Wall Street Journal: Elizabeth Warren Tells The Truth: She Admits The Patent Vaccine Waiver Is About Stealing All Pharma IP

Progressives are promoting President Biden’s waiver of U.S. Covid vaccine patents as necessary to save lives. So full marks for candor to Sen. Elizabeth Warren, who last week explained the real goal: set a precedent that erodes all pharmaceutical intellectual property protections in the U.S. and around the world. “Special [IP] protections for drug companies are an even bigger issue than COVID-19 alone,” the Massachusetts Senator said at a Senate Finance hearing with U.S. Trade Rep Katherine Tai on Wednesday. “I think it’s time now for our trade negotiators to take leadership and actively set rules that lower drug costs for American families.” What special protections? Drug makers receive less IP protection than other businesses under World Trade Organization (WTO) rules, which allow low-income countries to force drug makers to license patents during emergencies. But progressives believe IP protections shouldn’t exist at all for drugs and that their makers shouldn’t be rewarded for years of risky investment and innovation. (5/16)

Piscataquis Observer: Don’t Be Fooled By Big Pharma When It Comes To Lowering Drug Prices  

Hardly six months have gone by since Election Day, but corporate interests are once again flooding our TV screens with misleading, negative political ads. This time it’s the pharmaceutical companies and their allies, who are spending hundreds of thousands of dollars to warn you about a “socialist drug takeover” or American drugs “marching straight through Beijing.” In the ads, a dark and ominous voice tells you there’s a dangerous plan to seize the drug market and that you should call on me, your congressman in the 2nd District, to oppose it. (U.S. Rep. Jared Golden, D-Maine, 5/16)

The Gazette: Secretive Pharmacy Middlemen Drive Up Iowans’ Drug Costs 

Iowa’s U.S. Sen. Chuck Grassley again is turning his attention to exorbitant pharmaceutical prices. Grassley this year has filed a series of bipartisan bills meant to give Americans access to cheaper drugs. He’s calling special attention to an industry of secretive middlemen in the pharmacy business. Grassley and his fellow Republicans are firmly opposed to price-setting regulations, but they see a role for the federal government to play in ensuring transparency in the industry. Market forces are conspicuously absent in the health care industry, which conservative reformers say leads to higher prices and worse outcomes. (5/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF